68104-61-0

Usage

Uses

Used in Pharmaceutical Industry:
1-(4-TERT-BUTYLPHENYL)PIPERAZINE is used as a pharmaceutical intermediate for its potential role in the development of drugs targeting various medical conditions. Its unique structure and properties make it a promising candidate for creating novel therapeutic agents.
Used in Organic Synthesis:
1-(4-TERT-BUTYLPHENYL)PIPERAZINE is used as a building block in the synthesis of other organic compounds, contributing to the creation of new chemical entities with potential applications in various fields, including materials science, agrochemicals, and specialty chemicals.

InChI:InChI=1/C14H22N2/c1-14(2,3)12-4-6-13(7-5-12)16-10-8-15-9-11-16/h4-7,15H,8-11H2,1-3H3

Upstream product

• 769-92-6 4-tert-Butylaniline 
• 821-48-7 bis-(2-chloroethyl)amine hydrochloride 
• 110-85-0 piperazine 
• 3972-65-4 1-bromo-4-tert-butylbenzene 

Downstream Products

• 1239717-01-1 1-((1H-imidazol-4-yl)methyl)-4-(4-tert-butylphenyl)-piperazine 
• 1247040-90-9 C₁₈H₂₈N₂O₂ 
• 1204976-74-8 C₂₇H₃₃FN₄ 

Relevant academic research and scientific papers

(DiMeIHeptCl)Pd: A Low-Load Catalyst for Solvent-Free (Melt) Amination

(DiMeIHeptCl)Pd, a hyper-branched N-aryl Pd NHC catalyst, has been shown to be efficient at performing amine arylation reactions in solvent-free ("melt") conditions. The highly lipophilic environment of the alkyl chains flanking the Pd center serves as lubricant to allow the complex to navigate through the paste-like environment of these mixtures. The protocol can be used on a multi-gram scale to make a variety of aniline derivatives, including substrates containing alcohol moieties.

MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS

Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type 1 signal peptidase (SpsB), an essential protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.

NOVEL 1,6-DISUBSTITUTED-3-AMINO-4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[3,4-C]PYRIDIN-7-ONE COMPOUNDS AND PREPARATION THEREOF

Provided are a novel 1,6-disubstituted-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridin-7-one compound, a pharmaceutically acceptable salt compound thereof, a method for preparing the compound, and an anticancer pharmaceutical composition including the compound as an effective ingredient.

New pyrimido[5,4-b]indoles as ligands for α1-adrenoceptor subtypes

A new series of compounds were designed as structural analogues of the α1-AR ligand RN5 (4), characterized by a tricyclic 5H-pyrimido[5,4-b]indole-(1H,3H)2,4-dione system connected through an alkyl chain to a phenylpiperazine (PP) moiety. These compounds were synthesized and tested in binding assays on human α1A-AR, α1B-AR, and α1D-AR subtypes expressed in HEK293 cells. Several structural modifications were performed on the PP moiety, the tricyclic system, and the connecting alkyl chain. Many of the new molecules showed a preferential affinity for the α1D-AR subtype. Some compounds, including 39 and 40, displayed substantial α1D-AR selectivity with respect to α1A-AR, α1B-AR, serotonergic 5-HT1A, 5-HT1B, 5-HT2A, and dopaminergic D1 and D2 receptors. Two conformationally rigid analogues of 4, useful for studying the architecture of the receptor/ligand complex, were also prepared and tested. A subset of the new compounds was then used to evolve a preliminary pharmacophore model for α1D-AR antagonists, based on a more generalized model we had developed for α1-AR antagonists. This new model rationalized the relationships between structural properties and biological data of the pyrimido[5,4-b]indole compounds, as well as other compounds.